American Hospital Association December 4, 2024

The Centers for Medicare & Medicaid Services Dec. 4 announced that drug manufacturers bluebird bio, inc. (manufacturer of Lyfgenia) and Vertex Pharmaceuticals (manufacturer of Casgevy) will participate in its Cell and Gene Therapy Access Model. The voluntary model will test whether a CMS-led approach to developing and administering outcomes-based agreements for cell and gene therapies improves Medicaid beneficiaries’ health outcomes, broadens access to innovative...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, CMS, Govt Agencies, Payment Models, Pharma / Biotech, Value Based
Related Articles:
After slow start, ACA enrollment takes off
CMS says record 16.6 million have signed up for Jan. 1 Marketplace coverage
How has U.S. Spending on Health Care Changed Over Time?
CMS Launches New Program for Mental Health, OUD Treatment
CMS ending VBID model due to high costs

Share This Article